Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):15–24. doi: 10.1097/MED.0000000000000300

Table 1.

Molecular imaging in Neuroendocrine tumors (NETs). Recent advances

  1. Development of 68Gallium(68Ga)-labeled somatostatin analogues with PET/CT

  2. Investigation of the role of 18F-FDG PET/CT imaging either alone or combined with 68Ga-peptide PET/CT

  3. Studies of results of 18F-DOPA (18F-dihydroxyphenylalanine) PET/CT either alone or compared to 68Ga-peptide PET/CT

  4. Development of radiolabeled somatostatin receptor antagonists with enhanced sensitivity

  5. Development of other, novel radiolabeled somatostatin receptor ligands: 64Cu-labeled ligands for PET/CT; ligands with different linkers; alpha emitting ligands for enhanced Peptide radio-receptor therapy (PRRT)

  6. Development of novel radiolabeled ligands interacting with other receptors for imaging NETs or other tumors: radiolabeled GLP-1 receptor ligands; CCK2 receptor ligands: Bombesin receptor ligands (BB1, BB2, BB3); GIP receptor ligands and chemokine receptor CXCR4.